These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21497434)

  • 21. The use of pharmacotherapy for male patients with urgency and stress incontinence.
    Andersson KE
    Curr Opin Urol; 2014 Nov; 24(6):571-7. PubMed ID: 25144147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of vibegron, a novel β
    Maruyama I; Yamamoto S; Tsuchioka K; Yamazaki T
    Eur J Pharmacol; 2020 Jul; 878():173096. PubMed ID: 32259514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review.
    Kaplan SA; Roehrborn CG; Abrams P; Chapple CR; Bavendam T; Guan Z
    Int J Clin Pract; 2011 Apr; 65(4):487-507. PubMed ID: 21210910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
    Yamaguchi O
    Int J Urol; 2013 Jan; 20(1):28-39. PubMed ID: 23190275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.
    De Nunzio C; Brucker B; Bschleipfer T; Cornu JN; Drake MJ; Fusco F; Gravas S; Oelke M; Peyronnet B; Tutolo M; van Koeveringe G; Madersbacher S
    Eur Urol; 2021 Apr; 79(4):492-504. PubMed ID: 33402296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
    Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
    Serati M; Salvatore S; Uccella S; Cardozo L; Bolis P
    Eur Urol; 2009 Mar; 55(3):713-9. PubMed ID: 18584946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly.
    Kay GG; Granville LJ
    Clin Ther; 2005 Jan; 27(1):127-38; quiz 139-40. PubMed ID: 15763613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges for managing overactive bladder and guidance for patient support.
    Schabert VF; Bavendam T; Goldberg EL; Trocio JN; Brubaker L
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S118-22. PubMed ID: 19355801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overactive bladder symptoms and voiding dysfunction in neurologically normal women.
    Espuña-Pons M; Cardozo L; Chapple C; Sievert KD; van Kerrebroeck P; Kirby MG
    Neurourol Urodyn; 2012 Apr; 31(4):422-8. PubMed ID: 22419262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current role for combination therapy in male LUTS.
    Chung DE; Kaplan SA
    Arch Esp Urol; 2010 Jun; 63(5):323-32. PubMed ID: 20587837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fesoterodine for the treatment of overactive bladder.
    Tzefos M; Dolder C; Olin JL
    Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
    Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS
    BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mirabegron 25 mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction.
    Liao CH; Kuo HC
    Urology; 2018 Jul; 117():115-119. PubMed ID: 29630956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fesoterodine: a new agent for treating overactive bladder.
    Ellsworth P; Berriman SJ; Brodsky M
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of pharmacological management of nocturia with non-antidiuretic agents: does statistically significant equal clinically significant?
    Smith AL; Wein AJ
    BJU Int; 2011 May; 107(10):1550-4. PubMed ID: 21518417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.